Exclusive Summary

• **Innovative Dual-Target siRNA Mechanism**: UB039 targets both TGFβ1 and COX-2 to inhibit adipogenesis and inflammation, offering a potential First-in-Class genetic silencing approach distinct from traditional cytolytic agents.
• **Proprietary PNP Delivery Platform**: Utilizes the patented Histidine-Lysine Polymer (HKP) nanoparticle technology, effectively solving the major hurdle of siRNA stability and cell penetration, with broader platform potential.
• **Superior Safety Profile**: US Phase I data demonstrated histological efficacy in fat reduction with "excellent safety" and minimal Local Skin Reactions (LSRs), significantly outperforming the comparator (Kybella®) in tolerability.
• **High-Growth Aesthetic Market**: Positioned for the booming global non-invasive body contouring market ($3.41B by 2028 projection), meeting the demand for a painless injectable alternative to surgery.

Asset Materials

Contact Us for Full Materials